Dose study of PHIN-214 for mild to moderate cirrhosis
Part of Digestive system clinical trials.
This Phase 1 study tests how the medicine PHIN-214 behaves in the body and what dose is tolerable in people with Child-Pugh A or B liver cirrhosis. It may help doctors plan safer dosing for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis that doctors classify as Child-Pugh A or B
- You are between 18 and 75 years old
- Your BMI is between 18 and 40 at the screening visit
- If you are female who can become pregnant, you must not be pregnant or nursing and must use very reliable birth control during the study
- You do not have serious lung, heart, or blood pressure problems or major abnormal heart test results
- You have not had recent serious liver complications like bleeding, confusion needing hospital care, or severe kidney problems from liver disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests if phycocyanin (a natural blue pigment from spirulina) can help protect the liver and slow damage from fibrosis or cirrhosis. It may be an option if you have stable liver disease and are looking for supportive therapy.
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.